Compare MGM Resorts International (MGM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Vertex Pharmaceuticals Incorporated — how do they compare? MGM Resorts International trades at $29.91 (market cap $7.55B), while Vertex Pharmaceuticals Incorporated trades at $513.16 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 16.9× MGM Resorts International's market cap, and MGM Resorts International pays a 0.03% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MGM | VRTX | |
|---|---|---|
Market Cap | $7.55B | $127.55B |
Volume | 5,342,346 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $557.96 |
52-Week Low | $30.00 | $407.37 |
Typical Hold Time | 91 Days | 120 Days |
Enterprise Value | $34.85B | $121.68B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $30.00, down 1.77% on the day and facing bearish technical momentum despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $17.54B in 2025 but declining net margins to 1.17%. Recent market sentiment has been negatively impacted by the collapse of Barry Diller's $48.30 per share acquisition offer, though MGM is now exploring a potential bid for Diller's People Inc. Analyst consensus remains bullish with a $48.75 price target representing significant upside potential.
The stock presents a compelling value opportunity with attractive valuation metrics (P/E 18.19, P/S 0.45) and strong analyst support, but faces near-term headwinds from deal uncertainty and bearish technical signals. Key risks include execution challenges in potential M&A activity and ongoing margin pressure in the competitive gaming sector.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
